Navigation Links
Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation
Date:12/5/2011

TUSTIN, Calif., Dec. 5, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation  (OTCQX:RXPC) (OTCPK:RXPC), developer and marketer of the Onko-Sure® In Vitro Diagnostic (IVD) cancer test, announced today that the two abstracts it submitted to the 2012 Gastrointestinal Cancers Symposium (ASCO Conference) were accepted for presentation from among 730 abstracts submitted. The meeting will be held on January 19-21, 2012 at the Moscone West Building in San Francisco, California. Dr. Afsaneh Motamed-Khorasani, the Director of Oncology at Radient, will be presenting the data.

These two abstracts were the results of a collaborative study in the United States that compared the combined use of Onko-Sure® with carcinoembryonic antigen (CEA), the routine blood biomarker for colorectal cancer (CRC), and CEA alone. The clinical trial included a total of 564 subjects. Radient's proprietary Onko-Sure® cancer blood test combined with CEA test were more effective for the detection of colorectal cancer compared to using CEA test alone (an increase of 56% in the test sensitivity). Furthermore, the combined usage of Onko-Sure® and CEA in monitoring CRC recurrence showed a significant clinical advantage in terms of sensitivity (an increase of 35% in the test sensitivity). This was in line with a previous UK study published in peer reviewed journals in 2010.

Onko-Sure® has already been cleared by the US FDA for the monitoring of the treatment and recurrence in CRC. "We believe that Onko-Sure® provides a platform technology that is highly effective in the monitoring of colorectal cancer. Should an in vitro diagnostics test increase early detection of CRC recurrence when used adjunctively with other available diagnostic markers, the number of annual deaths due to CRC recurrence could be reduced. An increase in early detection has the potential to lead to an increased survival rate of patients," stated Radient Pharmaceuticals Chairman and CEO Douglas MacLellan.

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Paul Knopick at: pknopick@eandecommunications.com or 949-707-5365.

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Radient Contact:

Paul Knopick
E & E Communications
pknopick@eandecommunications.com
(Tel:) 949.707.5365


'/>"/>
SOURCE Radient Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Radient Pharmaceuticals Corporation Receives $500,000 in New Capital
2. Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital
3. Radient Pharmaceuticals Asks DHS Holding Co. to Retract News Release Saying It Will Enter Into Talks With Radient Pharmaceuticals Corporation
4. Radient Pharmaceuticals Announces FY 2011 Third Quarter Results
5. Merriman Capital Announces Sponsorship of Radient Pharmaceuticals Corporation on OTCQX
6. Radient Pharmaceuticals Corporation Joins OTCQX
7. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
8. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021
9. Arbor Pharmaceuticals Announces Filing of First NDA
10. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
11. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... -- Xynomic Pharmaceuticals, Inc., an oncology drug research and ... exclusive worldwide rights to develop, manufacture and commercialize ... hematological and solid tumors. To date ... clinical trials of Abexinostat in US, EU and ... completed, demonstrating that Abexinostat is clinically active in ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert ... Core benefits and advantages built into the home office sit stand solution are ... feel. Ability to gain the benefits embedded in the TaskMate Go are available ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, vice ... appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new ... 10. Dr. Bell comes to Liberty from the Ohio University Heritage College of ...
(Date:2/24/2017)... ... ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” (published by ... Schanssema describes the tragedies he saw, as well as his struggles with grief and ... unsure of the career path he wanted to take, found fulfillment in a career ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced ... the Chairman of the Management Committee when IFN was originally formed in 2002 where ... investor/owners and development of the business plan. He became the first paid employee ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning ... Gran Fondo of Marin. For the second year in a row, cyclists will ... , “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 ...
Breaking Medicine News(10 mins):